肺泰胶囊辅助治疗初治涂阳肺结核的临床研究

摘要

Objective:To explore the clinical curative effect and safety of Feitai capsule combined with anti tuberculosis western medicine in the treatment of new pulmonary tuberculosis.Methods:70 patients with new smear positive pulmonary tuberculosis were randomly divided into the treatment group with 42 cases and the control group with 28 cases.The treatment group was given Feitai capsule and 2HRZE/4HRE treatment for 6 months.The control group was given 2HRZE/4HRE treatment for 6 months.The sputum negative conversion,chest X-ray or chest CT lesions change situation were observed at the end of 2 months and 6 months. Results:At the end of 2 months,the sputum negative conversion rate of the treatment group was 92.86%,and the control group was 64.29%;the lesion apparent absorption rate of the treatment group was 52.38%,and the control group was 32.14%.At the end of 6 months,the sputum negative conversion rates of two group were 100%.The lesion apparent absorption rate of the treatment group was 23.81% ,and the control group was 14.29% .The treatment group was better than the control group(P<0.05).No adverse reactions were found in the pulmonary capsule.Conclusion:Feitai capsule combined with anti tuberculosis medicine in the treatment of pulmonary tuberculosis is excellence in the sputum negative conversion,lesion absorption and clinical symptoms improvement.It is an effective and safe anti tuberculosis traditional Chinese medicine preparation.%目的：探讨肺泰胶囊联合抗结核西药治疗初治肺结核的临床疗效和安全性。方法：70例初治涂阳肺结核患者，随机分为治疗组42例和对照组28例，治疗组给予肺泰胶囊+2HRZE/4HRE 治疗6个月，对照组给予2HRZE/4HRE治疗6个月，观察2个月末和6个月末痰结核菌阴转、胸片或胸CT上病灶变化情况。结果：治疗2个月末治疗组痰菌阴转率92.86%，对照组64.29%；治疗组病灶显吸收率52.38%，对照组32.14%；治疗6个月末两组痰菌阴转率均为100%；治疗组病灶显吸收率23.81%，对照组14.29%。治疗组均优于对照组(P＜0.05)。肺泰胶囊未见不良反应。结论：肺泰胶囊联合抗结核药物治疗肺结核在痰菌阴转、病灶吸收、临床症状改善等方面都有显效，是一种有效而安全的抗结核中药制剂。